Millipore Sigma Vibrant Logo

676504 VEGFR Tyrosine Kinase Inhibitor VI, AAL-993 - CAS 269390-77-4 - Calbiochem

The VEGFR Tyrosine Kinse Inhibitor VI, ALL-993, also referenced under CAS 269390-77-4, controls the biological activity of VEGFR Tyrosine Kinase. This small molecule/inhibitor is primarily used for Cancer applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII

View Products on Sigmaaldrich.com
676504
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
269390-77-4C₂₀H₁₆F₃N₃O

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
676504-10MGCN
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable anthranilamide that acts as a potent VEGFR inhibitor (IC50 = 130, 23, and 18 nM against VEGFR-1, -2, and -3, respectively; IC50 = 1.24 nM against VEGF-induced human VEGFR-2 phosphorylation in CHO cells) by targeting the ATP-binding site of VEGFR in its inactive "DFG-out" conformation and effectively suppresses tumor growths (50 to 100 mg/kg; p.o.) via its anti-angiogenesis activity in mice and rats in vivo, while inhibiting c-kit, CSF-1R/c-Fms, PDGFR-β, and c-Abl only at higher concentrations (IC50 = 236, 380, 640, and 2820 nM, respectively). AAL933 and two other VEGFR inhibitors, KRN633 and SU5416 (Cat. No. 676487), are also shown to inhibit hypoxia-induced HIF-1α expression (by <90% at 30 µM) and transcription activation. Unlike KRN633 and SU5416, AAL933 prevents only hypoxia-induced Erk, but not Akt, phosphorylation in HeLa cells.
      Catalogue Number676504
      Brand Family Calbiochem®
      Synonyms2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII
      References
      ReferencesBan, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.
      Product Information
      CAS number269390-77-4
      FormOff-white powder
      Hill FormulaC₂₀H₁₆F₃N₃O
      Chemical formulaC₂₀H₁₆F₃N₃O
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Regulatory Review
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      676504-10MGCN 04055977260533

      Documentation

      VEGFR Tyrosine Kinase Inhibitor VI, AAL-993 - CAS 269390-77-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Ban, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.

      Brochure

      Title
      New Products: Volume 3, 2012
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-June-2012 JSW
      Synonyms2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII
      DescriptionA cell-permeable anthranilamide that acts as a potent VEGFR inhibitor (IC50 = 130, 23, and 18 nM against VEGFR-1, -2, and -3, respectively; IC50 = 1.24 nM against VEGF-induced human VEGFR-2 phosphorylation in CHO cells) by targeting the ATP-binding site of VEGFR in its inactive "DFG-out" conformation, while inhibiting c-kit, CSF-1R/c-Fms, PDGFR-β, and c-Abl only at higher concentrations (IC50 = 236, 380, 640, and 2820 nM, respectively) and displaying little or no activity against EGFR/HER-1/ErbB (IC50 = 10.4 µM) and six other kinases (IC50 ≥10 µM). Reported to be orally available in mice (Conc. in plasma = 9.5, 4.7, 1.5, and 1.1 µM, respectively, 0.5 h, 1 h, 1.5 h, and 2 h after p.o. dosage of 50 mg/kg), rats, and dogs, and effectively suppress tumor growths (50 to 100 mg/kg; p.o.) via its anti-angiogenesis activity in various cancer models in vivo, including murine melanoma B16-BL6, rat mammary adenocarcinoma BN472, as well as human prostate cancer DU145-grafted mice in vivo. AAL933 and two other VEGFR inhibitors, KRN633 and SU5416 (Cat. No. 676487), are also shown to inhibit hypoxia- (1% O2) induced HIF-1α expression (by <90% at 30 µM) and transcription activation (IC50 = 6.53, 3.79, and 8.24 µM, respectively, by AAL933, KRN633, and SU5416 in HeLa-HRE-Luc reporter assays). However, unlike KRN633 and SU5416, AAL933 prevents only hypoxia-induced Erk, but not Akt, phosphorylation in HeLa cells.
      FormOff-white powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number269390-77-4
      Chemical formulaC₂₀H₁₆F₃N₃O
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Regulatory Review
      ReferencesBan, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.